Results 141 to 150 of about 2,540 (169)

Hypercholesterolaemia treated with inclisiran

Ugeskrift for Læger
In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects.
Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert   +2 more
openaire   +1 more source

Inclisiran

Journal of the American College of Cardiology, 2023
Christie M. Ballantyne, Abdul Mannan Khan Minhas, Carl E. Orringer   +2 more
openaire   +1 more source

Efficacy, benefit and safety of inclisiran

Clínica e Investigación en Arteriosclerosis (English Edition)
Hypercholesterolemia is a causal factor of atherosclerotic cardiovascular disease (ASCVD), which is one of the main causes of morbidity and mortality in Spain. The reduction of LDL cholesterol (LDL-C) decreases the risk of ASCVD and adverse cardiovascular events.
openaire   +2 more sources

Real-World Efficacy and Safety of Inclisiran

Journal of the American College of Cardiology
CHOLINET is a single-country, multicenter, observational, prospective, phase 4 registry of Italian patients initiating inclisiran as part of clinical management. Reimbursement criteria (Italian Medicines Agency [AIFA], GU 231-03.10.2022) include patients at very high cardiovascular (CV) risk with LDL-C of ≥70 mg/dL on statin ± ezetimibe.
Paola Gargiulo, Federica Marzano, Mario Crisci, Rossella Marcucci, Dario Bruzzese, Alessandro Maloberti, Filippo Maria Sarullo, Gennaro Galasso, Ciro Indolfi, Giuseppe Musumeci, Antonella Corleto, Paolo Calabrò, Stefano Carugo, Gavino Casu, Amedeo Picciolo, Marco Matteo Ciccone, Claudio Bilato, Alberto Polimeni, Francesco Giallauria, Angelo Catalano, Leonardo De Luca, Giampaolo Niccoli, Elio Venturini, Marco Pepe, Roberta Montisci, Natale Daniele Brunetti, Giuseppe Patti, Italo Porto, Alberto Margonato, Marina Floresta, Saverio Muscoli, Matteo Cameli, Giuseppe Andò, Emilio Di Lorenzo, Martina Berteotti, Cristina Giannattasio, Silvia Sarullo, Ciro Formisano, Assunta Di Costanzo, Fabrizio Delnevo, Ferdinando Varbella, Arturo Cesaro, Monica Franzese, Costantino Mancusi, Sara Fontanarosa, Mariafrancesca Di Santo, Ciro Cotticelli, Fabrizio Perrone Filardi, Stefania Paolillo, Giovanni Esposito, Alberto Corsini, Pasquale Perrone Filardi   +51 more
openaire   +2 more sources

The introduction of inclisiran

Journal of Prescribing Practice, 2021
openaire   +1 more source

UK deal over inclisiran

BMJ, 2020
Paula, Byrne, John, Cullinan, Barbara, Mintzes, Susan M, Smith   +3 more
openaire   +2 more sources

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Journal of the American College of Cardiology, 2021
R Scott Wright, Kausik K Ray, Frederick J Raäl   +2 more
exaly  

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

Journal of the American College of Cardiology, 2023
Anastasia Lesogor
exaly  

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol

Annals of Pharmacotherapy, 2023
Essie Samuel, Hua Ling, Drew W Cates
exaly  

NICE guidance on inclisiran should be reconsidered

BMJ, 2021
Paula, Byrne, Maryanne, Demasi, Susan M, Smith   +2 more
openaire   +2 more sources